Back to search

University of British Columbia

The role of relaxin in prostate cancer

Abstract

dc:description

Prostate cancer is the leading cause of cancer in men, and there is currently a lack of novel treatment options for this disease. Relaxin, part of the insulin superfamily, is a potent peptide hormone normally produced and secreted by the human prostate. cDNA and tissue microarray analyses, indicated that relaxin is highly overexpressed in prostate cancer progression to androgen independence (AI), and is negatively regulated by androgens. Characterization of the relaxin receptor, LGR7, in xenografts and human patient tissue microarrays (TMAs) indicated that LGR7 is expressed in the stroma and epithelia, suggesting that relaxin may act in an autocrine and/or paracrine fashion. Relaxin is known to increase angiogenesis through upregulation of vascular endothelial growth factor, and matrix metalloproteases. To elucidate novel pathways that may be upregulated by relaxin in prostate cancer, the effects of relaxin overexpression in the LNCaP prostate cancer xenograft model were analysed by gene expression microarrays. A novel discovery is that the protocadherinY (PCDHY)/Wnt pathway is upregulated by relaxin, resulting in β-catenin translocation from the cell membrane to the cytoplasm and upregulation of Wnt11, which can stimulate proliferation, transformation, and migration. Relaxin is well characterized in the uterus and ovary to increase insulin-like growth factor-I (IGF-I); relaxin may also increase IGF-I in prostate cancer. Since IGF-I and various other growth factor signaling is mediated by insulin receptor substrate-2 (IRS-2), and IGF-I signaling is important in prostate cancer progression to AI, we investigated the role of IRS-2 in LNCaP cells. IRS-2 mRNA is dramatically upregulated by androgens, and decreased by IGF-I in androgen treated cells. IRS-2 was knocked down using IRS-2 siRNA to explore the interaction between the IGF axis and androgen signalling. Combined IGF-I and androgen treatment reduced transcription of androgen regulated genes, prostate specific antigen, insulin degrading enzyme, vascular endothelial growth factor, and clusterin. This indicates that in the presence of IGF-I treatment, IRS-2 mRNA is required for normal androgen mediated transcription. Due to the potential for relaxin to induce proliferation and metastases, and the necessity of IRS-2 to mediate androgen action, relaxin and IRS-2 are intriguing targets for novel, targeted therapeutics for prostate cancer.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy - PhD
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Genetics
Grantor dc:publisher
University of British Columbia
Year dc:date
2007

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Thompson, Vanessa Camille

Rights

dc:rights
Statement dc:rights
  • For non-commercial purposes only, such as research, private study and education. Additional conditions apply, see Terms of Use https://open.library.ubc.ca/terms_of_use.
Language dc:language
eng

Identifiers

dc:identifier.*
Handle dc:identifier
http://hdl.handle.net/2429/31534

Chain of custody

source
Harvested from
University of British Columbia
Base URL
circle.library.ubc.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Thompson, Vanessa Camille. The role of relaxin in prostate cancer. doctoral thesis, University of British Columbia, 2007. http://hdl.handle.net/2429/31534